Source: Eur Respir J 2013; 42: 1155



Rating:

Share or cite this content

Citations should be made in the following way:
Lebecque Patrick. Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes. Eur Respir J 2013; 42: 1155

Member's Comments

No comment yet.

Related content which might interest you: Tezacaftor-ivacaftor for the treatment of cystic fibrosis: what’s next? Source: International Congress 2018 – Therapeutic breakthroughs Year in Review Year: 2018 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 What’s new in cystic fibrosis? Source: International Congress 2018 – Paediatric Year in Review Year: 2018 Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020 Year: 2020 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Predicting five year outcomes in adults with cystic fibrosis: Developing a predictive scoring model Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Does this patient have cystic fibrosis?  Source: International Congress 2017 – GR6 Paediatric Ground Round: an interactive session Year: 2017 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014 Measuring CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis? Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 Aspergillus-related lung disease in people with cystic fibrosis: can imaging help us to diagnose disease? Source: Eur Respir Rev, 30 (162) 210103; 10.1183/16000617.0103-2021 Year: 2021 Do causes influence clinical, functional and quality of life aspects on patients with bronchiectasis not associated with cystic fibrosis? Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 CFTR: cystic fibrosis and beyond Source: Eur Respir J 2014; 44: 1042-1054 Year: 2014